https://bioutah.org/sethera-therapeutics-polymacrocyclic-peptide-platform-selected-for-cdmrp-supported-mutant-p53-breast-cancer-program/2026-08-13T18:45:02ZBioUtahenSethera Therapeutics’ Polymacrocyclic Peptide Platform Selected for CDMRP-Supported Mutant p53 Breast Cancer Program2026-08-13T18:45:02ZBloghttps://bioutah.org/clene-announces-biomarker-analyses-to-be-included-in-nda-submission-supporting-als-accelerated-approval/2026-08-13T18:40:55ZBioUtahenClene Announces Biomarker Analyses To Be Included in NDA Submission Supporting ALS Accelerated Approval2026-08-13T18:40:55ZBloghttps://bioutah.org/cancervax-achieves-major-milestone-in-activating-human-killer-t-cells-against-cancer/2026-08-13T18:39:42ZBioUtahenCancerVax Achieves Major Milestone in Activating Human Killer T-Cells Against Cancer2026-08-13T18:39:42ZBloghttps://bioutah.org/teledyne-to-acquire-varex-imaging-corporation/2026-08-13T18:37:49ZBioUtahenTeledyne to Acquire Varex Imaging Corporation2026-08-13T18:37:49ZBlog